Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to assess the levels of 5,400 different ...

Data from two out of three positive studies faced the U.S. FDA’s Anesthetic and Analgesic Drug Products Advisory Committee as members examined the package submitted by Seikagaku Corp., of Tokyo, for ...

Brainaurora Medical Technology Ltd. debuted on the Hong Kong stock exchange Jan. 8 with a HK$583.18 million (US$74.93 million) IPO, offering about 181.11 million shares at HK$3.22 per share.

Researchers from Vera Salus Ricerca Srl and affiliated organizations have reported the discovery and preclinical characterization of novel sigma-1 receptor (S1R) antagonists as potential new analgesic ...

The wheels of the antibody-drug conjugate (ADC) juggernaut keep on turning, with Araris Biotech AG announcing a deal with a ...

Climb Bio Inc. has entered into an exclusive license agreement with Beijing Mabworks Biotech Co. Ltd. for rights to develop and commercialize MIL-116 (now CLYM-116), an anti-APRIL monoclonal antibody ...

Immune checkpoint blockade is one of the major advances in cancer treatment in recent years. However, the majority of immune ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...

Timing is everything. Just days after confirming a pause in the U.S. rollout of its Varipulse pulsed field ablation (PFA) catheter, Johnson & Johnson’s electrophysiology program received an epic ...

Zai Lab Ltd. has entered into a new strategic collaboration and worldwide license agreement with Medilink Therapeutics (Suzhou) Co. Ltd. to use Medilink’s TMALIN antibody-drug conjugate (ADC) platform ...

South Korea’s government continued to ramp up investment in its pharmaceutical and med-tech sector in 2025, including a 7.2% ...